Cash Flow Statement (Annual)

CAA / CalAtlantic Group, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Cash Flows From Operating Activities
  Net Income Loss -13,786 -11,724 -16,417 531,421 188,715 215,865 213,509 484,730
  Adjustments To Reconcile Net Income Loss To Net Cash Provided By Used In Operating Activities
Adjustments To Reconcile Net Income To Net Cash Provided By Used In Operating Activities
  Income Loss From Equity Method Investments -4,598 1,166 207 -2,090 949 -668 1,966 4,057
  Equity Method Investment Dividends Or Distributions 3,465 - 20 3,910 3,375 1,875 2,830 -
  Depreciation Depletion And Amortization 3,516 3,002 3,255 2,480 3,576 4,928 41,151 61,704
  Gain Loss On Sale Of Property Plant Equipment 2,611 37 179 -37 -17 -11 -39 -
  Share Based Compensation 12,864 11,848 11,239 7,151 9,015 8,469 15,624 17,794
  Excess Tax Benefit From Share Based Compensation Operating Activities -297 27 - - - 13,404 9,250 460
  Increase Decrease In Deferred Income Taxes - - - 454,000 -84,214 -98,998 -38,636 5,097
  Impairment Of Real Estate And Deposit Write Offs - 1,918 15,334 133 - - - -
  Net Cash Provided By Used In Operating Activities Continuing Operations - - - - -154,216 -362,397 -271,361 -
Changes In Cash And Equivalents Due To
  Increase Decrease In Accounts And Notes Receivable 8,440 -6,541 -5,358 -801 3,244 4,777 - -
  Increase Decrease In Mortgage Loans Held For Sale Net 24,718 -12,165 -43,661 46,339 2,543 52,838 42,871 -63,649
  Increase Decrease In Inventory Real Estate Owned 326,062 148,706 -282,447 315,639 415,312 642,008 497,836 306,896
  Increase Decrease In Inventory Real Estate Not Owned -2,805 27,861 -19,727 31,551 43,319 33,027 -34,770 37,728
  Increase Decrease In Prepaid Deferred Expense And Other Assets 118,265 -111,496 6,212 -2,618 -965 -9,306 2,998 -5,697
  Increase Decrease In Accounts Payable -18,554 -6,592 1,113 4,617 13,325 9,314 -89,461 20,099
  Increase Decrease In Accrued Liabilities -22,576 -61,843 7,852 9,155 7,949 34,223 26,462 21,541
  Net Cash Provided By Used In Operating Activities 419,830 -80,958 -322,613 -283,116 -154,216 -362,397 -271,361 322,314
Cash Flows From Investing Activities
  Payments To Acquire Interest In Joint Venture 28,600 39,513 14,689 57,458 24,328 10,506 91,453 29,118
  Proceeds From Dividends Received 3,524 7,640 8,593 14,530 4,763 18,010 19,582 39,735
  Cash Acquired From Acquisition - - - - - - 268,517 -
  Payments To Acquire Businesses Net Of Cash Acquired - - - 60,752 116,262 33,770 - -
  Payments For Proceeds From Other Investing Activities 2,225 1,582 2,217 1,525 8,030 4,754 11,972 7,688
    Net Cash Provided By Used In Investing Activities Continuing Operations - - - - -143,857 -31,020 184,674 -
  Net Cash Provided By Used In Investing Activities -27,301 -33,455 -8,313 -105,205 -143,857 -31,020 184,674 2,929
Cash Flows From Financing Activities
  Proceeds From Repayments Of Restricted Cash Financing Activities -9,748 -12,843 -1,559 3,347 6,565 -16,762 652 8,873
  Proceeds From Repayments Of Secured Debt -125,984 -83,562 -1,207 -866 -8,334 -1,458 - -
  Proceeds From Lines Of Credit - - - - - - 852,700 1,433,200
  Maturities Of Senior Debt - - - - - 4,971 29,789 -
  Repayments Of Senior Debt - 792,389 - 49,603 - 4,971 29,789 280,000
  Repayments Of Lines Of Credit - - - - - - 852,700 1,433,200
  Proceeds From Issuance Of Senior Long Term Debt 257,592 977,804 - 253,000 300,000 300,000 - 300,000
  Repayments Of Secured Debt - - - - 8,334 1,458 2,532 23,228
  Proceeds From Payments On Mortgage Credit Facilities 22,660 10,651 -16,464 -45,351 -8,708 11,454 -110,469 55,995
  Payments Of Debt Issuance Costs 8,764 17,215 4,575 11,761 5,316 6,230 1,016 2,669
  Payments Of Stock Issuance Costs - - 324 - - - - -
  Proceeds From Stock Options Exercised 641 2,611 1,278 13,039 13,536 6,771 1,000 -
  Proceeds From Issuance Of Common Stock - 186,443 - 71,847 - - - -
  Net Cash Provided By Used In Financing Activities -422,815 250,225 10,077 324,354 314,809 242,519 60,888 -303,710
  Payments For Repurchase Of Common Stock - - - - - 36,781 22,073 232,520
  Cash And Cash Equivalents Period Increase Decrease -30,286 135,812 -320,849 -63,967 16,736 -150,898 -25,799 21,533
  Payment Of Financing And Stock Issuance Costs - - - - - - - -
  Excess Tax Benefit From Share Based Compensation Financing Activities 297 27 - - - 13,404 9,250 -
  Cash And Cash Equivalents At Carrying Value - - 410,522 346,555 363,291 212,393 186,594 208,127
  Payments Of Dividends Common Stock - - - - - - 4,851 18,841
  Homebuilding Restricted Cash At End Of Period - - 31,372 26,900 21,460 38,222 35,990 28,321
  Financial Services Restricted Cash At End Of Period - - 1,295 2,420 1,295 1,295 22,914 21,710
  Cash And Equivalents And Restricted Cash At End Of Period - - 443,189 375,875 386,046 251,910 245,498 258,158
  Proceeds From Payments For Other Financing Activities - - - - - - -222 -200
    Net Cash Provided By Used In Financing Activities Continuing Operations - - - - 314,809 242,519 60,888 -

Peers - Operative Builders (1531)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 128195104